文献速递白血病

日本儿童白血病研究组ALL-97与ALL-02方案治疗的儿童急性淋巴细胞白血病骨坏死发生率低

Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group.
PubMed 文献 · J Clin Oncol · 2018-01-23

该回顾性分析纳入日本儿童白血病研究组ALL-97和ALL-02两项研究的1662例急性淋巴细胞白血病患儿,24例发生骨坏死,年龄≥10岁是唯一显著危险因素;≥10岁患儿5年累积骨坏死发生率在ALL-97方案为7.2%,ALL-02方案为5.9%,均低于既往报道。

要点

  • 1662例患儿中24例发生骨坏死,其中23例年龄>10岁。
  • 多因素分析中年龄≥10岁是骨坏死的唯一显著危险因素(P<.001)。
  • ≥10岁患儿5年累积骨坏死发生率ALL-97方案7.2%,ALL-02方案5.9%。

核心结论

  • JACLS的ALL-97和ALL-02研究中骨坏死发生率低。
  • 骨坏死的唯一危险因素为年龄≥10岁,即使在高危患者中骨坏死发生率也显著低于既往研究报道。
  • 结果提示地塞米松(DEX)总量以及DEX与左旋门冬酰胺酶的给药方式可能影响骨坏死发生率。

研究设计与样本

  • 回顾性分析日本儿童白血病研究组(JACLS)ALL-97和ALL-02两项研究中的急性淋巴细胞白血病患儿,共1662例,ALL-97方案635例,ALL-02方案1027例。

主要发现

  • 1662例中24例发生骨坏死,ALL-97方案635例中12例,ALL-02方案1027例中12例。
  • 24例骨坏死患者中23例年龄大于10岁。
  • 多因素分析中年龄≥10岁是骨坏死的唯一显著危险因素(P<.001)。
  • ≥10岁患儿5年累积骨坏死发生率ALL-97方案为7.2%(95%CI,4.0%至12.6%),ALL-02方案为5.9%(95%CI,3.3%至10.4%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Osteonecrosis (ON) is a serious complication of the treatment of childhood acute lymphoblastic leukemia (ALL); however, data relating to ON in Asian pediatric patients with ALL are scarce. Therefore, we performed a retrospective analysis of cohorts of Japanese patients with ALL to clarify the incidence, clinical characteristics, and risk factors of ON. Patients and Methods The incidence and characteristics of ON were determined in patients with ALL (n = 1,662) enrolled in two studies from the Japan Association of Childhood Leukemia Study (JACLS) group (n = 635 and n = 1,027 patients treated with the ALL-97 and ALL-02 protocols, respectively). Results In total, 24 of 1,662 patients suffered from ON, of which 12 of 635 and 12 of 1,027 patients were treated with the ALL-97 and the ALL-02 protocol, respectively. Of the 24 patients, 23 were older than 10 years. In multivariate analysis, age (≥ 10 years) was the sole significant risk factor for ON ( P < .001). Separate evaluation of patients ≥ 10 years of age indicated a 5-year cumulative incidence of ON of 7.2% (95% CI, 4.0% to 12.6%) and 5.9% (95% CI, 3.3% to 10.4%) in the ALL-97 and the ALL-02 protocol, respectively, which was lower than reported previously, despite an administration of dexamethasone (DEX) similar to that in comparable studies; however, concomitant administration of DEX and l-asparaginase was reduced in the JACLS protocols. Conclusion We identified a low frequency of ON in the JACLS ALL-97 and ALL-02 studies. Although the sole risk factor for ON was age (≥ 10 years), even among high-risk patients, ON incidence was significantly lower than that reported in previous studies. These results suggest that, not only the total amount of DEX, but also how DEX and l-asparaginase are administered, which affects the clearance of DEX, may be associated with ON incidence in patients with ALL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sakamoto K, Imamura T, Kihira K, et al. Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. J Clin Oncol. 2018. PMID: 29360413. doi:10.1200/JCO.2017.75.5066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。